Browsing by Author "Anderson, Kenneth"
Now showing items 21-32 of 32
-
A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
Bae, Jooeun; Prabhala, Rao; Voskertchian, Annie; Brown, Andrew; Maguire, Craig; Richardson, Paul; Dranoff, Glen; Anderson, Kenneth C.; Munshi, Nikhil C. (2014)We evaluated a cocktail of HLA-A2-specific peptides including heteroclitic XBP1 US184-192 (YISPWILAV), heteroclitic XBP1 SP367-375 (YLFPQLISV), native CD138260-268 (GLVGLIFAV) and native CS1239-247 (SLFVLGLFL), for their ... -
A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells
Das, Deepika Sharma; Ray, Arghya; Das, Abhishek; Song, Yan; Oronsky, Bryan; Richardson, Paul; Scicinski, Jan; Chauhan, Dharminder; Anderson, Kenneth C. (2016)The hypoxic bone-marrow (BM) microenvironment confers growth/survival and drug-resistance in multiple myeloma (MM) cells. Novel therapies targeting the MM cell in its hypoxic-BM milieu may overcome drug resistance. Recent ... -
A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function
Vallet, Sonia; Pozzi, Samantha; Patel, Kishan; Vaghela, Nileshwari; Fulciniti, MariaTeresa; Veiby, Petter; Hideshima, Teru; Santo, Loredana; Cirstea, Diana; Scadden, David T; Anderson, Kenneth C; Raje, Noopur (2014)Upregulation of cytokines and chemokines is a frequent finding in multiple myeloma (MM). CCL3 (also known as MIP-1α) is a pro-inflammatory chemokine whose levels in the MM microenvironment correlate with osteolytic lesions ... -
Preclinical Validation of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma
Ray, Arghya; Song, Yan; Chauhan, Dharminder; Anderson, Kenneth (Springer, 2020-02-05)Bone marrow plasmacytoid dendritic cells (pDCs) in patients with multiple myeloma (MM) promote tumor growth, survival, drug resistance, and immune suppression. Understanding the molecular signaling crosstalk among the tumor ... -
Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance via Targeting Ubiquitin Receptor Rpn13
Du, Ting; Song, Yan; Ray, Arghya; Chauhan, Dharminder; Anderson, Kenneth (American Society of Hematology, 2018-05-18)Our prior study showed that inhibition of 19S proteasome-associated ubiquitin receptor Rpn13 can overcome bortezomib-resistance in MM cells. Here, we performed proteomic analysis of Rpn13 inhibitor (RA190)-treated MM cells ... -
RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS
Cottini, Francesca; Hideshima, Teru; Xu, Chunxiao; Sattler, Martin; Dori, Martina; Agnelli, Luca; Hacken, Elisa ten; Bertilaccio, Maria Teresa; Antonini, Elena; Neri, Antonino; Ponzoni, Maurilio; Marcatti, Magda; Richardson, Paul G.; Carrasco, Ruben; Kimmelman, Alec C.; Wong, Kwok-Kin; Caligaris-Cappio, Federico; Blandino, Giovanni; Kuehl, W. Michael; Anderson, Kenneth C.; Tonon, Giovanni (2014)Oncogene–induced DNA damage elicits genomic instability in epithelial cancer cells, but apoptosis is blocked through inactivation of the tumor suppressor p53. In hematological cancers, the relevance of ongoing DNA damage ... -
Retraction: Fatty Acid Synthase is a Novel Therapeutic Target in Multiple Myeloma
Okawa, Yutaka; Hideshima, Teru; Ikeda, Hiroshi; Raje, Noopur; Vallet, Sonia; Kiziltepe, Tanyel; Yasui, Hiroshi; Enatsu, Sotaro; Pozzi, Samantha; Breitkreutz, Iris; Cirstea, Diana; Santo, Loredana; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl (Blackwell Publishing Ltd, 2008)This study investigated the biological significance of the inhibition of fatty acid synthase (FAS) in multiple myeloma (MM) using the small molecule inhibitor Cerulenin. Cerulenin triggered growth inhibition in both MM ... -
A Review of Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma
Hideshima, Teru; Raje, Noopur; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl (Dove Medical Press, 2008)Lenalidomide (also known as Revlimid®, CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity ... -
Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma
Prabhala, Rao H.; Fulciniti, Mariateresa; Pelluru, Dheeraj; Rashid, Naim; Nigroiu, Andreea; Nanjappa, Puru; Pai, Christine; Lee, Saem; Prabhala, Nithya S.; Bandi, Rajya Lakshmi; Smith, Robert; Lazo-Kallanian, Suzan B.; Valet, Sonia; Raje, Noopur; Gold, Jason S.; Richardson, Paul G.; Daley, John F.; Anderson, Kenneth C.; Ettenberg, Seth A.; Di Padova, Franco; Munshi, Nikhil C. (2015)We have previously demonstrated that interleukin-17A (IL-17) producing Th17 cells are significantly elevated in blood and bone marrow (BM) in multiple myeloma (MM) and IL-17A promotes MM cell growth via the expression of ... -
Targeting the UPS as Therapy in Multiple Myeloma
Chauhan, Dharminder; Bianchi, Giada; Anderson, Kenneth Carl (BioMed Central, 2008)The coordinated regulation of cellular protein synthesis and degradation is essential for normal cellular functioning. The ubiquitin proteasome system mediates the intracellular protein degradation that is required for ... -
Targeting Tryptophan Catabolic Kynurenine Pathway Enhances Antitumor Immunity and Cytotoxicity in Multiple Myeloma
Ray, Arghya; Song, Yan; Du, Ting; Tai, Yu-Tzu; Chauhan, Dharminder; Anderson, Kenneth (Springer Science and Business Media LLC, 2019-08-28) -
A Unique Three-dimensional SCID-polymeric Scaffold (SCID-synth-hu) Model for In Vivo Expansion of Human Primary Multiple Myeloma Cells
Calimeri, T; Battista, E; Conforti, F; Neri, P; Di Martino, M T; Rossi, M; Foresta, U; Piro, E; Ferrara, F; Amorosi, A; Bahlis, N; Tagliaferri, P; Causa, F; Tassone, P; Anderson, Kenneth Carl; Munshi, Nikhil C (Nature Publishing Group, 2011)